Dr Philip Molyneaux is a Clinical Senior Lecturer in Interstitial lung disease and an Honorary Consultant at the Royal Brompton Hospital, where he is the director of the Clinical Research Facility.
Philip qualified from Guy's, King's and St Thomas' School of Medicine in 2004, where he completed an intercalated BSc. in Molecular Genetics. He undertook his SHO training at Guy’s and St Thomas’ and upon completion of the MRCP attained an NIHR Academic Clinical Fellow position in Respiratory medicine at Imperial College. He spent the next two years training at St Mary’s Hospital and working with Professors Cookson, Moffatt and Johnston studying the respiratory microbiome in COPD.
An Asmarley training fellowship allowed him to undertake a PhD examining the host response to the respiratory microbiome in Idiopathic Pulmonary Fibrosis as part of the Prospective Study of Fibrosis In the Lung Endpoints (PROFILE) study with Professor Maher.
Having completed his clinical training in Respiratory and Critical Care Medicine he returned to Imperial joining the Fibrosis Research Group as a Senior Clinical Lecturer. He was awarded the Action for Pulmonary Fibrosis Mike Bray Fellowship which enabled him to establish his research group studying the interaction between the respiratory tract microbiota and innate immunity in pulmonary fibrosis. He is Associate Editor at European Respiratory Journal Open Research and BMC Pulmonary Medicine. He sits on the British Thoracic Society Science and Advisory board as well as the ILD Registry committee.
et al., 2022, Short-term lung function changes predict mortality in patients with fibrotic hypersensitivity pneumonitis, Respirology, ISSN:1323-7799
et al., 2022, Common idiopathic pulmonary fibrosis risk variants are associated with hypersensitivity pneumonitis, Thorax, ISSN:0040-6376
et al., 2022, Candidate role for toll-like receptor 3 L412F polymorphism and infection in acute exacerbation of idiopathic pulmonary fibrosis, American Journal of Respiratory and Critical Care Medicine, ISSN:1073-449X
et al., 2021, Outcomes and incidence of PF-ILD according to different definitions in a real-world setting, Frontiers in Pharmacology, Vol:12, ISSN:1663-9812
Wu Z, Molyneaux PL, 2021, Choosing pharmacotherapy for ILD in patients with connective tissue disease, Breathe, Vol:17, ISSN:1810-6838